Table 5.

Active PPI use: outcomes based on PPI dosage (n = 286)*.

	Low (n = 70)	Standard (n = 190)	High (n = 26)	p-value**
Hospital admission within two weeks of COVID testing (n,%)	68 (97.1%)	182 (95.8%)	25 (96.2%)	.88
ICU admission (n,%)	16 (22.9%)	52 (27.4%)	9 (34.6%)	.50
Hospital length of stay, days (median, range)	1 (1–33)	3 (1–32)	3.5 (1–45)	.07
Oxygen use (n,%)	Mechanical ventilation: 7 (10%) BPAP: 1 (1.4%) Supplemental: 47 (67.1%) None: 15 (21.4%)	Mechanical ventilation: 28 (14.7%) BPAP: 1 (0.5%) Supplemental: 106 (55.8%) None: 55 (28.9%)	Mechanical ventilation: 6 (23.1%) BPAP: 0 Supplemental: 14 (53.8%) None: 6 (23.1%)	.47
30-day mortality (n,%)	10 (14.3%)	37 (19.5%)	7 (26.9%)	.35

*PPI Proton pump inhibitor.

**Based on separate chi square or Kruskal Wallis tests, as appropriate.